EBV-VCA IgG ELISA kit

Specifications

Product Data
Description	EBV-VCA IgG ELISA kit
Size	1 x 96 wells
Format	8x12 divisible strips
Assay Type	Solid Phase Sandwich ELISA
Assay Length	3 hours
Signal	Colorimetric
Sample Type	Serum
Sample Volume	10 µl
Specificity	This kit is used for quantitative detection human Epstein-Barr Virus-Viral Capsid Antigen (EBV-VCA) IgG
Reactivity	Human
Cross Reactivity	There is no detectable cross-reactivity with other relevant proteins.
Interference	No significant interference observed with available related molecules.
Components	1. Microwells coated with EBV-VCA antigen: 12x8x1 2. Sample Diluent: 1 bottle (ready to use): 22 ml 3. Calibrator: 1 Vial (ready to use): 1ml 4. Positive Control: 1 vial (ready to use): 1ml 5. Negative Control: 1 vial (ready to use): 1ml 6. Enzyme conjugate: 1 bottle (ready to use): 12ml 7. TMB Substrate: 1 bottle (ready to use): 12ml 8. Stop Solution: 1 bottle (ready to use): 12ml 9. Wash concentrate 20X: 1 bottle: 25ml
Background	Epstein-Barr virus (EBV) is a herpes virus known to cause infectious mononucleosis (IM). EBV infection may demonstrate a wide spectrum of clinical symptoms. The majorities of primary EBV infections are transmitted via saliva, occur during childhood, and are sub-clinical. In the U.S., 50% of the population demonstrate EBV antibodies before the age of 5 years; 80% by adulthood. Transfusion-associated EBV infections have also been reported. Epstein-Barr virus has also been associated in the pathogenisis of two human cancers, Burkitt's lymphoma and nasopharyngeal carcinoma. Burkitt's lymphoma is primarily observed in Sub-Sahara Africa, especially in African children, and in New Guinea. Nasopharyngeal carcinoma is observed in Asia, most notably in Southern China.

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.